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Abstract
Mutations in the arginine vasopressin receptor 2 (AVPR2)
gene can cause X-linked nephrogenic diabetes insipidus
(NDI) characterized by the production of large amounts of
urine and an inability to concentrate urine in response to
the antidiuretic hormone vasopressin. We have identiﬁed
a novel mutation in the AVPR2 gene (L170P) located in
the fourth transmembrane domain in a Danish NDI male.
Analysis of the mutant receptor in Madin-Darby Canine
Kidney cell culture revealed that AVPR2-L170P was re-
tained in the endoplasmic reticulum, and the expression
was dramatically downregulated compared to wild-type
AVPR2. Inhibition of the lysosome resulted in increased
intracellular accumulation of AVPR2-L170P, indicating
that AVPR2-L170P is downregulated via the lysosome.
Inhibition of the proteasome resulted in plasma membrane
localization of AVPR2-L170P, although the overall levels
of AVPR2-L170P were unchanged.
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Introduction
Fine-tuning of urine concentration occurs in the renal col-
lecting duct by the actions of the antidiuretic hormone argi-
ninevasopressin(AVP). AVPbinds toarginine vasopressin
receptor2(AVPR2)onthebasolateralplasmamembraneof
renal collecting duct principal cells, thereby inducing apical
plasma membrane insertion of aquaporin-2 leading to in-
creased water uptake and urine concentration [1, 2]. Neph-
rogenic diabetes insipidus (NDI), which can be either
inherited or acquired, is characterized by the excretion of
large volumes of dilute urine and resistance to the action of
vasopressin. Almost 90% of congenital NDI is inherited in
an X-linked recessive manner due to mutations in the
AVPR2 gene residing in the Xq28 region, while 10% is
autosomalNDIcausedbymutationsintheaquaporin2gene
(AQP2) [1]. More than 200 putative disease-causing muta-
tions within the AVPR2 gene have been reported [3] and
functional characterization of some of these mutant recep-
tors have revealed receptor malfunction at different levels
such as receptors with drastically reduced binding afﬁnity
for vasopressin (type 1), defective intracellular trafﬁcking
(type 2) or reduced receptor transcription (type 3) [1].
In the present report, we describe a novel mutation in the
AVPR2 gene in a Danish male with NDI. Cell-based experi-
ments demonstrate that this novel mutant is likely mis-
folded. We propose that, in NDI, the accumulation of the
misfolded protein is non-toxic since other functions of the
principal cell of the collecting duct are intact.
Case history
A 30-year-old Caucasian male patient had a history of pol-
yuria and polydipsia from infancy. During early childhood,
he was followed by a paediatric clinic. Later in life, how-
ever, he only had sporadic contact with hospitals. The pa-
tient is normally developed without cognitive deﬁcits and is
gainfully employed.
After referral, further investigations revealed a daily
urine output of typically 13 L with low osmolality,
75 mOsm/kg, despite high plasma AVP concentration. A
water deprivation test showed an inability to produce con-
centrated urine before and after administration of exoge-
nous AVP. Subsequent treatment with hydrochlorothiazide
lowered the patient’s daily urinary output by ~3 L [4]. Due
to high mictional volumes suggesting distended urinary
bladder, he was instructed to void at regular intervals,
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medium, provided the original work is properly cited.irrespective of whether urine had accumulated or not. None
of the patient’s relatives (Figure 1) had a similar history of
polyuria and polydipsia. The patient’s mother and sister
agreed to be genetically tested for the mutation. The father
is adopted and healthy. The mother’s sister and her three
sons are clinically healthy and have therefore not been
genetically tested. Blood samples were taken from the pa-
tient, his sister and mother. The mother was diagnosed as a
heterozygous carrier of the mutation, while the sister was
not. The mother did not wish to participate in further in-
vestigations and therefore we were not able to conduct
urine sampling in order to test for possible skewed X-chro-
mosome inactivation [5]. However, it was reported that she
as a child had extraordinary thirst and suffered from enu-
resis nocturna until the age of 10 (Tomas M. Christensen,
personal communication). The daughter of the patient is an
obligate carrier of the mutation but due to her young age
(1 year), genetic testing and urine analysis has not been
performed.
Experimental results
Sequence analysis of the AVPR2 gene was performed as
previously described [6] and revealed a novel missense
mutation (L170P) in the fourth transmembrane domain of
AVPR2.
Constructs
The L170P mutation was introduced into the pEGFP-V2R
construct using (forward) CCTTCTCGCTCCTTCCCA-
GCCTGCCCCAGC and (reverse) GCTGGGGCAGGCTG-
GGAAGGAGCGAGAAGG primers and the QuikChange
Site-Directed Mutagenesis Kit (Stratagene). The mutation
was conﬁrmed by sequencing.
Immunostaining, imaging and western blotting
For transient transfections, Madin-Darby Canine Kidney
(MDCK)GIIcellsweretransfected,stained24-hpost-trans-
fection, imaged and analysed as previously described [6].
To generate a cell line stably expressing AVPR2-L170P-
GFP, a tetracycline/doxycyclin-inducible MDCK cell line
was generated using the Flp-In T-REx core kit (Invitrogen)
according to the manufacturer’s protocol. MDCK type II
cells were maintained in Dulbecco’s modiﬁed Eagle’s me-
dium (Gibco) supplemented with 5% fetal calf serum (PAA
Laboratories), ciproxin, L-glutamin and 1% non-essential
amino acids. All transfection procedures were performed
using calcium phosphate. Brieﬂy, to stably introduce an
FLP recognition target (FRT) recombination site, pFRT-
LacZeo (Invitrogen) was linearized with XmnI and
transfected into the MDCK cells. Stable transfectants were
selectedusing0.5mg/mLzeocin,andinsertionintotheFRT
sitewasconﬁrmedbybluestainingusingtheb-GalStaining
Kit (Invitrogen). To stably introduce a Tet-repressor, cells
weretransfectedwithFspI-linearizedpcDNA6-TR(Invitro-
gen) and cells were selected using 5 lg/mL blasticidin. To
identifyasingleclonewithminimalleakinessandtoidentify
the optimal time of induction, cell lines stably expressing
green ﬂuorescent protein (GFP) were generated by co-
transfection of pcDNA5-FRT-TO-GFP plasmid with pOG44
(encoding the ﬂp recombinase; Invitrogen) in a ratio of 1:9.
Transfectants were isolated using selection with 0.1 mg/mL
hygromycin and analysed via western blotting and ﬂuores-
c e n c em i c r o s c o p yt od e t e r m i n einduction. A suitable clone
was chosen for subsequent experiments as described below.
AVPR2-L170P-GFP was subcloned into the pcDNA5/
FRT/TO (Invitrogen) and cells were co-transfected
with pcDNA5-FRT-TO-AVPR2-L170P-GFP plasmid and
pOG44 using Lipofectamine 2000. Transfectants were iso-
lated using selection with 0.1 mg/mL hygromycin and
Fig. 1. Pedigree of NDI relatives. Open circles, women; open squares, men. Roman numerals, the generation; circles with a central dot, obligatory
carriers; closed squares,affected subjects. A slash (/) through a symbolindicates that the subject is deceased. The probandis shownby an arrow. The year
of birth is beneath the subject.
Functional characterization of novel AVPR2 mutation 159blasticidin and analysed via ﬂuorescence microscopy to
determine induction. Following 16 h of 10 lg/lL tetracy-
cline, lysomal degradation was inhibited by the lysosomal
protease inhibitor chloroquine (100 lM) for 4 h, or the
proteasome was inhibited by a 4-h incubation with the
proteasome inhibitor MG-132 (10 lM; Sigma), control
cells were incubated with dimethyl sulfoxide (DMSO).
The experiment was performed three times.
LysoTracker Red (Molecular Probes) was added 30 min
before ﬁxation. Primary antibodies were polyclonal GFP
(A11122; Molecular Probes), polyclonal Calreticulin (Af-
ﬁnity BioReagent), monoclonal Cathepsin D (TriChem
ApS) and monoclonal Clone 58K-9 (Sigma–Aldrich).
For western blotting, cells were lysed in sodium dodecyl
sulfate sample buffer and western blotting was perfomed
via a standard protocol. Antibody was GFP polyclonal anti-
body from ABCAM. Equal amounts of proteins were
loaded as conﬁrmed by Coomassie staining.
Imaging was performed on a Zeiss 200M microscope
using the MetaMorph software and analysis was performed
using ImageJ [7].
Localization of AVPR2-L170P-GFP in cell culture
InMDCKcellstransientlytransfectedwithAVPR2-L170P-
GFP or wild-type AVPR2-GFP, wild-type AVPR2-GFP
was localized to the plasma membrane, with some
AVPR2-GFP localized to the Golgi as visualized by label-
ling with the Golgi marker Golgi 58K Protein (Figure 2A).
AVPR2-L170P-GFP could not be detected following
transient transfections by normal epi-ﬂuorescence micro-
scopy,suggestingthattheAVPR2-L170P-GFPwasdramat-
ically downregulated compared to the wild type. Increasing
the signal of the mutant AVPR2-L170P-GFP with a GFP
antibody revealed that the mutant was localized intracellu-
larly but did not colocalize with the Golgi marker (Figure
2B). Co-staining with calreticulin, a marker for the endo-
plasmic reticulum (ER), revealed a large degree of colocal-
ization between AVPR2-L170P-GFP and the ER (Figure
2C). Moreover, cells transfected with AVPR2-L170P-
GFP had greatly increased lysosomes as detected by Lyso-
tracker Red (Figure 2D); however, there was no
colocalizationbetweenAVPR2-L170P-GFPandlysosomes.
Normally, wild-typeAVPR2-GFPislocalizedto theplasma
membrane, from which it is internalized and degraded in the
lysosome[8,9].ThelackofcolocalizationbetweenAVPR2-
L170P-GFP and lysosomes could be due to degradation of
the GFP tag. The increase in lysosomal size could be due to
degradationofAVPR2-L170P-GFPorcouldbeasecondary
effect of AVPR2-L170P-GFP accumulation in the ER,
which could disturb trafﬁcking of other proteins.
Effect of lysosome and proteasome inhibition on the
expression and localization of AVRR2-L170P-GFP in
cell culture
TodeterminethecellularfateoftheunstableAVPR2-L170P,
inhibition of lysosomal degradation was investigated in
the cell line stably expressing AVPR2-L170P-GFP under a
tetracycline-inducible promoter. Some AVPR2-L170P-GFP
expression was observed even without tetracycline (Figure
3B), indicating a leakiness of the promoter. AVPR2-L170P-
GFP expression was induced by 16-h incubation with 10 lg/
mL tetracycline, followed by a 4-h incubation with either
DMSO or the lysosome inhibitor chloroquine (100 lM).
Inhibition of lysosomal degradation by chloroquine re-
sulted in increased intracellular accumulation of AVPR2-
L170P-GFP (Figure 3A). Moreover, cells treated with
chloroquine had larger lysosomes (Figure 3, stained with
Cathepsin D antibodies) and inhibition of lysosomal deg-
radation resulted in colocalization of AVPR2-L170P-GFP
with lysosomes (Figure 3, overlays). Western blot analysis
of wild-type AVPR2-GFP showed bands at ~68 kDa and a
broad 57-kDa band corresponding to the glycosylated
forms of the protein and a 46-kDa band corresponding to
the lysosomal degradation product [8]. Interestingly, west-
ern blot analysis of AVPR-L170P-GFP (Figure 3B) re-
vealed a 68-kDa band corresponding to the full-length
glycosylated protein and a 46-kDa band corresponding to
the degradation product, but no bands around 57-kDa were
observed, indicating that there might be a deﬁciency in
glycosylation of AVPR2-L170P-GFP. The lack of
AVPR2-L170P-GFP glycosylation could be the primary
cause for ER accumulation, or more likely, it could be a
secondary effect due to receptor misfolding, resulting in ER
retention and subsequent degradation in the lysosome.
Compared to wild-type AVPR2-GFP, the intensity of the
46-kDa degradation product was larger than the 68-kDa
band, indicating rapid degradation of AVPR2-L170P-
GFP. This was reversed by treatment with lysosomal in-
hibitor chloroquine, which resulted in increased intensity of
the 68-kDa band compared to the 46-kDa band (Figure 3B)
Since ER-retained V2R mutants are often degraded in
the proteasome [10], we also tested if AVPR2-L170P-GFP
could be degraded in this organelle. Following incubation
with an inhibitor of proteasomal degradation, MG-132,
there was a signiﬁcant change in the localization of
AVPR2-L170P-GFP, which relocated from the ER to the
plasma membrane (Figure 4A); however, there was no
change in the expression levels of AVPR2-L170P-GFP
following MG-132 treatment (Figure 4B) and unlike lyso-
somal inhibition, we did not see a change in the ratio be-
tween the 68-kDa full-length protein and the 46-kDa
degradation product following proteasome inhibition. This
indicates that AVPR2-L170P-GFP is not degraded via the
proteasome, but inhibition of proteasome degradation
could lead to a general release of proteins from the ER.
Discussion
Congenital X-linked NDI is a rare disease affecting 8.8 of
1 000 000 male live births [11]. We have identiﬁed a Dan-
ish male patient with congenital X-linked NDI due to a
missense mutation in the fourth transmembrane domain
of the AVPR2 (L170P).
When expressed in cell cultures, the present AVPR2-
L170P mutant was shown to be trapped intracellularly and
colocalized with ER markers suggesting that AVPR2-
L170P mutant is misfolded and degraded. The intracellular
retention has been characterized as a type 2 mutation and
functional studies conducted to date have shown that the
majority of mutant AVPR2 receptors are of this type [1].
160 L. N. Nejsum et al.We are proposing to classify the inherited diseases
characterized by the accumulation of misfolded proteins
into two groups: in the ﬁrst group, there is toxic accumula-
tion of the misfolded protein and a gain-of-toxic function
mechanism now extensively explored in alpha-1-antitrypsin
deﬁciency and in familial neurohypophyseal diabetes insip-
idus, both dominant disorders [12, 13].
In the second group, the function of the cell where this
accumulation takes place remains intact; this is the case
with AVPR2 mutations where the other important function
of the principal cell of the collecting tubule, namely the
reabsorption of Na
1 through the epithelial sodium channel
(ENaC) channel, remains intact since there is no evidence
of loss of function of the ENaC channel in male patients
bearing AVPR2 mutations [14].
NDI is associated with a large urine production and if
not recognized in early childhood, it may result in mental
retardation due to dehydration. When diagnosed, urine
volumes can be somewhat reduced by administering thia-
zide diuretics along with prostaglandin inhibitors [2, 4];
Fig. 2. (A) Wild-type AVPR2-GFP transiently expressed in MDCK cells and stained with the Golgi marker G58K. Wild-type AVPR2-GFP localizes to
cell–cell contacts of MDCK cells and to the Golgi region. (B). AVPR2-L170P-GFP transiently expressed in MDCK cells and stained with the Golgi
marker G58K. AVPR2-L170P-GFP does not seem to localize to the Golgi compartment. (C) AVPR2-L170P-GFP transiently expressed in MDCK cells
and stained with the ER marker calreticulin. AVPR2-L170P-GFP localizes to intracellular structures with some overlap with the ER marker calreticulin.
(D) AVPR2-L170P-GFP transiently expressed in MDCK cells. Cells were loaded with Lysotracker Red before ﬁxation, which shows that cells
expressing AVPR2-L170P-GFP had larger lysosomes than surrounding cells, although AVPR2-L170P-GFP did not colocalize, which could be due
to degradation of the GFP-tag in lysosomes. Please note that samples B, C and D have been stained with antibody against the GFP tag since they were
otherwise not bright enough for imaging. Scale bar is 10 lm.
Functional characterization of novel AVPR2 mutation 161however, at present, no cure for congenital NDI is
available.
In working toward a potential cure for NDI, a great
advance in potentially treating NDI comes from work by
Suga et al. [15]. They successfully used in vivo gene
therapy to transfer AQP2 to rat collecting ducts, which
temporarily and partially rescued lithium-induced NDI.
This is the ﬁrst time a gene has successfully been incorpo-
rated into the renal collecting duct and this technique
shows great promise for potentially treating patients with
different forms of NDI caused by mutations in AVPR2 or
AQP2.
Recent studies in cell cultures have shown that different
pharmacologicalchaperonesareabletorescuesomeAVPR2
foldingmutantsbyrestoringtheirplasmamembraneexpres-
sion [16] or inducing their intracellular activation [17]. The
listofspeciﬁcchemicalchaperonesisrapidlyexpandingand
chaperonesabletorescueAVPR2foldingmutantsfromboth
theER(typeA)[18]andtheER/Golgiintermediatecompart-
ment(typeB)[19]havebeenidentiﬁedandpotentially,these
chaperones can be used in vivo to rescue patients carrying
AVPR2 mutations leading to NDI [20, 21]. Since AVPR2-
L170P-GFP relocalized from the ER to the plasma
membrane upon treatment with the proteasome inhibitor
Fig. 3. (A) Representative images of AVPR2-L170P-GFP stably expressed in MDCK cells 16 h after induction with tetracycline followed by 4 h of
incubation with DMSO or chloroquine (100 lM). There is a marked accumulation of AVPR2-L170P-GFP in cells treated with chloroquine compared to
controls (DMSO). Moreover, following chloroquine treatment, AVPR2-L170P-GFP is localized in larger structures, which colocalize with the lysosomal
marker Cathepsin D. (B) Western blot analysis of equal amount of protein from cells stably expressing AVPR2-L170P-GFP, either not induced or
induced by tetracycline, and transiently expressing wild-type AVPR2-GFP probed with a GFP antibody. A 68-kDa band was observed in all samples as
well as a 46-kDa band corresponding to the lysosomal degradation product. The 68-kDa band was decreased in intensity and the 46-kDa degradation
product was increased in intensity in AVPR2-L170P-GFP compared to wild-type AVPR2-GFP; however, this was reversed by inhibition of lysosome
degradation by chloroquine. Moreover, a broad 57-kDa band in wild-type AVPR2-GFP was completely absent from AVPR2-L170P-GFP. Cells not
induced by tetracycline still show signiﬁcant levels of AVPR2-L170P-GFP, indicating a leaky promoter. Scale bar is 10 lm.
162 L. N. Nejsum et al.MG-132,itisverylikelythatchaperonescouldaidincorrect
folding of the mutant, thereby bypassing lysosomal degra-
dation leading to a rescue of the mutant receptor.
Acknowledgements. We thank Dr Ralf Schuelein, Forschungsinstitut fu ¨r
Molekulare Pharmakologie, Berlin, Germany for generously providing us
with the AVP2-GFP plasmid. We thank W. James Nelson for help and
discussions. We thank Liselotte Spurr, Bispebjerg Hospital and Connie
Jakobsen Juhl, Aarhus University, for excellent technical assistance. This
work was supported by fellowships to LNN from the Danish Medical
Foundation and the Lundbeck Foundation and a grant to D.G.B. by the
Canadian Institute of Health Research (MOP-86479); Dr D.G.B. holds a
Canada Research Chair in The Genetics of Renal Diseases. J.H.R. was
supported by a Rubicon grant (825.06.010) of the Dutch Organization for
Scientiﬁc Research.
Conﬂict of interest statement. None declared.
References
1. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes
insipidus. J Am Soc Nephrol 2005; 16: 2836–2846
2. Robertson GL. Antidiuretic hormone. Normal and disordered func-
tion. Endocrinol Metab Clin North Am 2001; 30: 671–694, vii
3. Spanakis E, Milord E, Gragnoli C. AVPR2 variants and mutations in
nephrogenic diabetes insipidus: review and missense mutation signiﬁ-
cance. J Cell Physiol 2008; 217: 605–617
4. Kim GH, Lee JW, OH YK et al. Antidiuretic effect of hydrochloro-
thiazide in lithium-induced nephrogenic diabetes insipidus is associ-
ated with upregulation of aquaporin-2, Na-Cl co-transporter, and
epithelial sodium channel. J Am Soc Nephrol 2004; 15: 2836–2843
5. Nomura Y, Onigata K, Nagashima T et al. Detection of skewed X-
inactivation in two female carriers of vasopressin type 2 receptor gene
mutation. J Clin Endocrinol Metab 1997; 82: 3434–3437
6. Nejsum LN, Nelson WJ. A molecular mechanism directly linking E-
cadherin adhesion to initiation of epithelial cell surface polarity. J Cell
Biol 2007; 178: 323–335
7. Rasband WS. ImageJ. Bethesda, MD: U.S. National Institutes of
Health http://rsb.info.nih.gov/ij/ 1997–2009
8. Bouley R, Lin HY, Raychowdhury MK et al. Downregulation of the
vasopressin type 2 receptor after vasopressin-induced internalization:
involvement of a lysosomal degradation pathway. Am J Physiol Cell
Physiol 2005; 288: C1390–C1401
9. Robben JH, Knoers NV, Deen PM. Regulation of the vasopressin V2
receptor by vasopressin in polarized renal collecting duct cells. Mol
Biol Cell 2004; 15: 5693–5699
10. Robben JH, Knoers NV, Deen PM. Characterization of vasopressin
V2 receptor mutants in nephrogenic diabetes insipidus in a polarized
cell model. Am J Physiol Renal Physiol 2005; 289: F265–F272
11. Arthus MF, Lonergan M, Crumley MJ et al. Report of 33 novel
AVPR2 mutations and analysis of 117 families with X-linked neph-
rogenic diabetes insipidus. J Am Soc Nephrol 2000; 11: 1044–1054
12. Hidvegi T, Ewing M, Hale P et al. An autophagy-enhancing drug
promotes degradation of mutant alpha1-antitrypsin Z and reduces
hepatic ﬁbrosis. Science 2010; 329: 229–232
13. Birk J, Friberg MA, Prescianotto-Baschong C et al. Dominant pro-
vasopressin mutants that cause diabetes insipidus form disulﬁde-
linked ﬁbrillar aggregates in the endoplasmic reticulum. J Cell Sci
2009; 122(Pt 21): 3994–4002.
14. Bankir L, Fernandes S, Bardoux P et al. Vasopressin-V2 receptor
stimulation reduces sodium excretion in healthy humans.. J Am Soc
Nephrol 2005; 16: 1920–1928
15. SugaH,NagasakiH,KondoTetal.Noveltreatmentforlithium-induced
nephrogenic diabetes insipidus rat model using the Sendai-virus vector
carrying aquaporin 2 gene. Endocrinology 2008; 149: 5803–5810
16. Robben JH, Deen PM. Pharmacological chaperones in nephrogenic
diabetes insipidus: possibilities for clinical application. BioDrugs
2007; 21: 157–166
17. Robben JH, Kortenoeven ML, Sze M et al. Intracellular activation of
vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by
nonpeptide agonists. Proc Natl Acad Sci U S A 2009; 106:
12195–12200
18. Wuller S, Wiesner B, Lo ¨fﬂerAet al. Pharmacochaperones post-transla-
tionally enhance cell surface expression by increasing conformational
stability of wild-type and mutant vasopressin V2 receptors. JB i o lC h e m
2004; 279: 47254–47263
19. Hermosilla R, Oueslati M, Donalies U et al. Disease-causing V(2)
vasopressin receptors are retained in different compartments of the
early secretory pathway. Trafﬁc 2004; 5: 993–1005
20. Bernier V, Morello JP, Zarruk A et al. Pharmacologic chaperones as a
potential treatment for X-linked nephrogenic diabetes insipidus. JA m
Soc Nephrol 2006; 17: 232–243
21. Los EL, Deen PM, Robben JH. Potential of nonpeptide (ant)agonists
to rescue vasopressin V2 receptor mutants for the treatment of X-
linked nephrogenic diabetes insipidus. J Neuroendocrinol 2010; 22:
393–399
Received for publication: 13.1.11; Accepted in revised form: 24.1.11
Fig. 4. (A) Representative images of AVPR2-L170P-GFP stably expressed in MDCK cells 16 h after induction with tetracycline followed by 4 h of
incubation with DMSO or MG-132. There is a marked relocalization of AVPR2-L170P-GFP from the ER to the plasma membrane following inhibition
of the proteasome with MG-132 compared to DMSO. (B) Representative western blot analysis using GFP antibodies. MDCK cells stably expressing
AVPR2-L170P-GFP induced by tetracycline followed by a 4-h treatment with either DMSO or the proteasome inhibitor MG-132. A 68-kDa band
corresponding to the non-glycosylated form of AVPR2-L170P-GFP was present in all lanes as well as a 46-kDa band presumed to be a degradation
product. There was no signiﬁcant difference in the intensity of the bands between DMSO and MG-132-treated cells. Scale bar is 10 lm.
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